文献速递神经肿瘤神经重症

恶性胶质瘤开颅术后早期停用全身糖皮质激素:真实世界人群队列研究

Early withdrawal of systemic corticosteroid following malignant glioma craniotomy: a real-world population-based cohort study.
PubMed 文献 · J Neurooncol · 2026-02-19

基于TriNetX数据库的回顾性队列研究,倾向性评分匹配后比较恶性胶质瘤开颅术后早期停用激素(术后7天内停药且3个月内未再用)与晚期停用者的结局;早期停用与6个月、1年、2年生存改善及脑膜炎、脑脊液漏、颅内出血、静脉血栓栓塞和早期再手术发生率降低相关。

要点

  • 恶性胶质瘤开颅术后7天内停用激素与生存改善相关。
  • 早期停用者脑膜炎、脑脊液漏、静脉血栓栓塞及再手术率更低。
  • 术后激素撤停时机仍需前瞻性研究验证。

核心结论

  • 恶性胶质瘤开颅术后早期停用激素与生存改善和围手术期并发症减少相关。

研究设计与样本

  • 回顾性队列分析,使用TriNetX数据库;粗队列共34693例患者,倾向性评分匹配后两组各5922例。

主要发现

  • 早期停用激素与生存改善相关:6个月HR 0.57(p < 0.001),1年HR 0.65(p < 0.001),2年HR 0.70(p < 0.001)。
  • 早期停用组脑膜炎发生率1个月0.4% vs. 1.3%、6个月0.7% vs. 2.3%(均p < 0.001)。
  • 脑脊液漏1个月0.6% vs. 1.5%、6个月0.9% vs. 2.5%(均p < 0.001)。
  • 颅内出血1个月2.2% vs. 2.8%(p = 0.041)、6个月3.8% vs. 5.5%(p < 0.001);静脉血栓栓塞1个月2.4% vs. 4.6%、6个月4.5% vs. 9.3%(均p < 0.001);早期再手术4.9% vs. 11.3%(p < 0.001)。

关键数值与推荐

  • 早期停用定义为术后7天内停用激素且3个月内未重新启用;晚期停用定义为术后7天至3个月内有任何激素使用。

临床怎么用

  • 对恶性胶质瘤开颅术后患者,可考虑在术后7天内撤停激素并在3个月内避免再用,以兼顾生存与减少感染、血栓等并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexamethasone is commonly administered perioperatively in malignant glioma craniotomies to mitigate peritumoral edema and associated mass effects. However, prolonged steroid exposure impairs survival outcomes through immunosuppression. The optimal timing for postoperative steroid withdrawal remains unclear. This study investigates the association between early postoperative corticosteroid withdrawal and outcomes following malignant glioma craniotomy. METHODS: A retrospective cohort analysis was conducted using the TriNetX database. Propensity score matching (PSM) was performed to form two balanced groups comparing patients with early steroid withdrawal (discontinuation of within 7 days postoperatively and no reinitiation within 3 months) versus late steroid withdrawal (any steroid use between 7 days and 3 months postoperatively). Primary outcomes were survival at 6 months, 1 year, and 2 years. Secondary outcomes included perioperative complications including meningitis, cerebrospinal fluid (CSF) leak, intracranial hemorrhage, venous thromboembolism, and early reoperation. RESULTS: A total of 34,693 patients were included in the crude cohort. After PSM, 5922 patients were included in both groups. Early withdrawal of corticosteroid was associated with improved survival (6 months: HR 0.57, p < 0.001, 1 year: HR 0.65, p < 0.001, 2 years: HR 0.70, p < 0.001). Additionally, early steroid withdrawal was associated with lower incidence of meningitis (1-month: 0.4% vs. 1.3%, p < 0.001; 6-month: 0.7% vs. 2.3%, p < 0.001), CSF leak (1-month: 0.6% vs. 1.5%, p < 0.001; 6-month: 0.9% vs. 2.5%, p < 0.001), intracranial hemorrhage (1-month: 2.2% vs. 2.8%, p = 0.041; 6-month: 3.8% vs. 5.5%, p < 0.001), venous thromboembolism (1-month: 2.4% vs. 4.6%, p < 0.001; 6-month: 4.5% vs. 9.3%, p < 0.001), and early reoperation (4.9% vs. 11.3%, p < 0.001). CONCLUSIONS: In patients undergoing malignant glioma craniotomy, early postoperative steroids withdrawal was associated with improved survival and lower incidence of perioperative complications.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wong CE, Kuo YC, Chen PW, et al. Early withdrawal of systemic corticosteroid following malignant glioma craniotomy: a real-world population-based cohort study. J Neurooncol. 2026. PMID: 41712084. doi:10.1007/s11060-026-05464-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。